Publications & Presentations
Molecular Therapy|July 2, 2024
Human plasma cells engineered to secrete bispecifics drive effective in vivo leukemia killing
Nature Biotechnology|June 17, 2024
B cells as drug factories
Keystone Symposia on Emerging Cellular Therapies|January 24, 2024
Development of an Ex Vivo Precision Gene Engineered B Cell Medicine Platform that Produces Active and Sustained Levels of Therapeutic Proteins with Broad Utility
ASH 2023|December 10, 2023
Development of an Ex Vivo Precision Gene Engineered B Cell Medicine that Produces Active and Sustained Levels of FIX for the Treatment of Hemophilia B
Society for Immunotherapy of Cancer (SITC)|November 4, 2023
“Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics”
ASGCT 2023|May 19, 2023
Rhesus Antibody Secreting Cells Differentiated ex vivo from B Cells Engraft Without Preconditioning in an Autologous Host and Represent a Novel Modality for Cell and Gene Therapy
ASGCT 2023|May 18, 2023
CRISPR Engineering Primary Human B Cells for Sustained Secretion of Therapeutic Biologics
ASGCT 2023|May 16, 2023
Development of an ex vivo Gene Engineered B Cell Medicine Platform with Precision, Modularity, and Broad Therapeutic Utility
Nature Communications|October 16, 2022
Ex vivo engineered human plasma cells exhibit robust protein secretion and long-term engraftment in vivo
PEGS Boston Summit|May 5, 2022
Rick Morgan, Be Bio CSO, PEGS Boston Summit: Engineered B Cells as a Novel Off-the-Shelf Oncology Therapy
Nature Reviews Immunology|October 6, 2020
Transcriptional regulation of memory B cell differentiation
Frontiers in Immunology|September 11, 2019
Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells
Molecular Therapy|November 21, 2017
Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells
Trends in Cancer|December 1, 2016
